Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873621 | 1.00 | CASP2 (0.61) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL13120985 | 0.91 | CASP2 (0.57) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL25878486 | 0.91 | CASP2 (0.57) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL19455850 | 0.85 | CASP2 (0.62) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL7349053 | 0.84 | CASP2 (0.61) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL11211245 | 0.84 | CASP2 (0.61) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL12557459 | 0.83 | CASP2 (0.65) | CASP2NAAAFAAHSLC6A5DNM1 | |
| SCHEMBL24393473 | 0.83 | CASP2 (0.69) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL889156 | 0.83 | CASP2 (0.69) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL889294 | 0.83 | CASP2 (0.69) | CASP2NAAAFAAHDNM1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181065-A1 | N-ALKYLDIAMIDE COMPOUNDS AND GELS COMPRISING THE SAME | RHODIA OPERATIONS (FR) | 2020-06-11 | — | — | US | disclosed |
| US-20200181065-A1 | N-ALKYLDIAMIDE COMPOUNDS AND GELS COMPRISING THE SAME | RHODIA OPERATIONS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2019068914-A1 | FORMULATIONS COMPRISING SURFACTANTS, ORGANIC LIQUIDS AND VISCOSIFIERS | RHODIA OPERATIONS (FR) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068913-A1 | FORMULATIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | RHODIA OPERATIONS (FR) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068912-A1 | N-HYDROCARBYLDIAMIDE COMPOSITION WITH GELATING PROPERTIES | RHODIA OPERATIONS (FR) | 2019-04-11 | — | — | WO | disclosed |
| EP-3466398-A1 | N-HYDROCARBYLDIAMIDE COMPOSITION WITH GELATING PROPERTIES | RHODIA OPERATIONS (FR) | 2019-04-10 | — | — | EP | disclosed |
| EP-3440050-A1 | N-ALKYLDIAMIDE COMPOUNDS AND GELS COMPRISING THE SAME | Rhodia Operations (FR) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174615-A1 | N-ALKYLDIAMIDE COMPOUNDS AND GELS COMPRISING THE SAME | RHODIA OPERATIONS (FR) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181065-A1 | N-ALKYLDIAMIDE COMPOUNDS AND GELS COMPRISING THE SAME | CNR2, CNR1, PTGDR2 | CASP2 1898/4885NAAA 123/4885FAAH 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.